DDInter1407 DDInter948
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Peginterferon alfa-2a {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etanercept
Peginterferon alfa-2a {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Etanercept
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam